Happy New Year!
Our first #RheumJC of 2019 will be Thursday, January 31st at 10pm Eastern Time / 9pm Central Time (click here to find this in your local time zone).
We’ll be discussing the Lancet article: Efficacy and safety of ustekinumab, an IL–12 and IL–23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
If you’re new to #RheumJC, take a look at our Intro to Twitter page or our Journal Club Getting Started Guide.
As always:
- Please remember to try to stay on topic whenever possible.
- Be polite and courteous.
- Do not violate HIPAA.
We welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at rheumjc@rheumjc.com.